Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Pharmacology of EP262 at the American Academy of Allergy, Asthma and Immunology Annual Meeting
Escient Pharmaceuticals, a clinical-stage company advancing novel small-molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the presentation of preclinical data related to the company’s EP262 development program at the American Academy of Allergy.
EP262 is a potent, highly selective antagonist of MRGPRX2, which inhibits agonist-induced mast cell degranulation and represents a novel potential treatment for a broad range of mast cell-mediated disorders. The presentation highlights preclinical data demonstrating that EP262 potently inhibits MRGPRX2-mediated degranulation of human mast cells and inhibits mast cell degranulation-induced vascular permeability in proprietary humanized MRGPRX2 transgenic mice.